User login
Key clinical point: Women who started receiving statins after the diagnosis of breast cancer (BC) had a significantly decreased risk for breast cancer-specific death (BCD).
Major finding: The risk for BCD was significantly lower in the overall cohort of patients who used vs never used statins (hazard ratio [HR] 0.74; 95% CI 0.63-0.86) and in the subgroup of patients with estrogen receptor-positive BC (HR 0.77; 95% CI 0.63-0.94), post-menopausal women (HR 0.74; 95% CI 0.63-0.88), and women with advanced stage BC (HR 0.65; 95% CI 0.49-0.84).
Study details: Findings are from a large, population-based cohort study including 14,976 women with newly diagnosed BC, of which 4060 patients received statins after the diagnosis of BC.
Disclosures: This study was supported by the Auckland Medical Research Foundation, New Zealand. The authors declared no conflict of interests.
Source: Scott OW et al. Post-diagnostic statin use and breast cancer-specific mortality: A population-based cohort study. Breast Cancer Res Treat. 2023 (Mar 17). Doi: 10.1007/s10549-022-06815-w
Key clinical point: Women who started receiving statins after the diagnosis of breast cancer (BC) had a significantly decreased risk for breast cancer-specific death (BCD).
Major finding: The risk for BCD was significantly lower in the overall cohort of patients who used vs never used statins (hazard ratio [HR] 0.74; 95% CI 0.63-0.86) and in the subgroup of patients with estrogen receptor-positive BC (HR 0.77; 95% CI 0.63-0.94), post-menopausal women (HR 0.74; 95% CI 0.63-0.88), and women with advanced stage BC (HR 0.65; 95% CI 0.49-0.84).
Study details: Findings are from a large, population-based cohort study including 14,976 women with newly diagnosed BC, of which 4060 patients received statins after the diagnosis of BC.
Disclosures: This study was supported by the Auckland Medical Research Foundation, New Zealand. The authors declared no conflict of interests.
Source: Scott OW et al. Post-diagnostic statin use and breast cancer-specific mortality: A population-based cohort study. Breast Cancer Res Treat. 2023 (Mar 17). Doi: 10.1007/s10549-022-06815-w
Key clinical point: Women who started receiving statins after the diagnosis of breast cancer (BC) had a significantly decreased risk for breast cancer-specific death (BCD).
Major finding: The risk for BCD was significantly lower in the overall cohort of patients who used vs never used statins (hazard ratio [HR] 0.74; 95% CI 0.63-0.86) and in the subgroup of patients with estrogen receptor-positive BC (HR 0.77; 95% CI 0.63-0.94), post-menopausal women (HR 0.74; 95% CI 0.63-0.88), and women with advanced stage BC (HR 0.65; 95% CI 0.49-0.84).
Study details: Findings are from a large, population-based cohort study including 14,976 women with newly diagnosed BC, of which 4060 patients received statins after the diagnosis of BC.
Disclosures: This study was supported by the Auckland Medical Research Foundation, New Zealand. The authors declared no conflict of interests.
Source: Scott OW et al. Post-diagnostic statin use and breast cancer-specific mortality: A population-based cohort study. Breast Cancer Res Treat. 2023 (Mar 17). Doi: 10.1007/s10549-022-06815-w